Quince Therapeutics stock price target lowered to $8 by Citizens JMP

Published 12/08/2025, 12:16
Quince Therapeutics stock price target lowered to $8 by Citizens JMP

Investing.com - Citizens JMP lowered its price target on Quince Therapeutics Inc. (NASDAQ:QNCX) to $8.00 from $9.00 on Tuesday, while maintaining a Market Outperform rating on the stock. Currently trading at $1.60, the company’s stock remains well below analyst targets ranging from $4 to $10. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment.

The firm expressed confidence in management’s execution in completing enrollment for the pivotal NEAT trial for eDSP, a treatment for Ataxia-Telangiectasia (A-T). Citizens JMP highlighted several factors supporting potential trial success, including QNCX’s focus on the high dose of eDSP, which showed greater effectiveness in the prior ATTeST trial. InvestingPro data shows the company maintains a strong financial position with more cash than debt on its balance sheet, though it’s currently burning through cash - a common characteristic for clinical-stage biotech companies.

The primary analysis population of 6-9 year olds is viewed favorably as this age group demonstrated the greatest treatment benefit in previous studies. Additionally, the company has secured a special protocol assessment (SPA) from the FDA for NEAT, which evaluates a more selective primary endpoint that showed pronounced effects in earlier trials.

Citizens JMP assigned eDSP a 60% probability of success in A-T treatment based on existing data and projects peak sales of approximately $800 million ($550 million U.S./$240 million EU), noting this estimate could be conservative given the diagnosed total addressable market for A-T in the U.S. is approximately $2 billion. With a current market capitalization of just $85.8 million and an impressive 131.88% return over the past year, investors seeking detailed financial analysis and additional insights can access more exclusive data through InvestingPro, which offers 8 additional key insights about QNCX’s financial health and market position.

The firm also viewed positively QNCX’s selection of OPCH as its eDSP provider, which is expected to streamline the product launch process for both the company and patients.

In other recent news, Quince Therapeutics, Inc. has announced a private placement agreement that is set to provide approximately $11.5 million in upfront proceeds. This financing deal is priced at $1.325 per share, offering a 10% premium over the previous closing price of $1.20. The agreement also includes warrants that could potentially generate an additional $10.4 million if fully exercised. In another development, JMP Securities initiated coverage of Quince Therapeutics with a Market Outperform rating, setting a price target of $9.00. This rating is based on a risk-adjusted, discounted cash flow analysis of the company’s pipeline. Additionally, Quince Therapeutics has appointed Dr. Hassan Abolhassani, an immunology expert, to its Scientific Advisory Board. Dr. Abolhassani joins as the ninth member of the board, which comprises experts in rare diseases. These recent developments highlight Quince Therapeutics’ strategic moves in financial and scientific advancements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.